Four approved COVID-19 therapeutics are reasonably priced, offering not only improved patient outcomes but potentially saving tens of thousands of dollars in hospital costs associated with treating severe disease, according to a draft cost-effectiveness analysis by the Institute for Clinical and Economic Review (ICER).